COMPOSITION
Carva® 75 mg tablet: Each enteric coated tablet contains Aspirin BP 75 mg.

INDICATION
Carva® 75 has an antithrombotic action, mediated through inhibition of platelet activation, which has been shown to be useful in secondary prophylaxis following myocardial infarction and in patients with unstable angina or cerebral transient ischemic attacks.

DOSAGE AND ADMINISTRATION
150 mg at diagnosis and 75 mg daily thereafter.

CONTRAINDICATION AND PRECAUTION
Hypersensitivity to aspirin, hypoprothrombinaemia, haemophilia and peptic ulceration.

Salicylates may enhance the effects of anticoagulants, oral hypoglycaemic, phenytoin, probenecid and may increase the toxicity of sulphonamides. These may also precipitate bronchospasm or induce attacks of asthma in susceptible subjects.

Patients using enteric-coated aspirin should be advised against ingesting antacids simultaneously, to avoid premature drug release.

SIDE EFFECT
Salicylates may induce hypersensitivity, asthma, urate kidney stones, chronic gastro-intestinal blood loss, tinnitus, nausea and vomiting. The special coating of aspirin helps to reduce the incidence of side-effects resulting from gastric irritation.

DRUG INTERACTION
Aspirin is generally contraindicated in patients taking oral anticoagulants because of the risk of bleeding.

USE IN PREGNANCY AND LACTATION
Aspirin does not appear to have teratogenic effects. However, prolonged pregnancy and labour, with increased bleeding before and after delivery, decreased birth weight and increased rate of stillbirth were reported with high blood salicylate levels. Aspirin should be avoided during the last 3 months of pregnancy.
As aspirin is excreted in breast milk, it should not be used by patients who are breast feeding.

**STORAGE CONDITION**
Store below 30°C. Keep all medicines out of the reach of children.

**HOW SUPPLIED**
Carva® 75 tablet : Box containing 10 x 10 tablets in strip pack.